The effects of pharmacologic agents for type 2 diabetes mellitus on body weight

Postgraduate Medicine

Volumn 120, Issue 2, 2008, Pages 5-17

  Pi Sunyer, F Xavier ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Amylin; Bariatric surgery; Diabetes mellitus, type 2; Exenatide; Liraglutide; Obesity; Orlistat; Rimonabant; Sibutramine; Sitagliptin; Vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; RAMIPRIL; RECOMBINANT HUMAN INSULIN; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; VILDAGLIPTIN;

ABDOMINAL PAIN; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVENING DOSAGE; FECAL URGENCY; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MONOTHERAPY; MORNING DOSAGE; MORTALITY; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL EDEMA; RHINOPHARYNGITIS; SIDE EFFECT; SUICIDAL IDEATION; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; WEIGHT LOSS;

EID: 54049111104     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.07.1785     Document Type: Article

References (122)

1. National Institutes of Health. Type 2 diabetes fact sheet. http://www.nih.gov/about/researchresultsforthepublic/Type2Diabetes.pdf. Accessed December 10, 2007.
2. Centers for Disease Control and Prevention. National diabetes fact sheet. http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx. 2005. Accessed December 10, 2007.
3. Centers for Disease Control and Prevention. Diabetes: disabling disease to double by 2050. http://www.cdc.gov/nccdphp/publications/aag/ddt.htm. 2007. Accessed December 10, 2007.
4. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.
5. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999 2000. JAMA. 2002;288(14):1723-1727.
6. Palamara KL, Mogul HR, Peterson SJ, Frishman WH. Obesity: new perspectives and pharmacotherapies. Cardiol Rev. 2006;14(5):238-258.
7. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291(23):2847-2850.
8. Centers for Disease Control and Prevention. Diabetes: public health GIS news and information. November 2004. http://www.cdc.gov/search.do?q=129. 6+overweight&spell=1&ie=utf8. Accessed December 10, 2007.
9. Rappaport EB, Usher DC. Obesity, insulin resistance, and type 2 diabetes in children and adolescents. Pediatr Ann. 2006;35(11):822-826. (Pubitemid 44902460)
10. Pincock S, Zimmet P. Fighting the "diabesity" pandemic. Lancet. 2006;368(9548):1643.
11. Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973;29:457-496.
12. Hart CL, Hole DJ, Lawlor DA, Davey Smith G. How many cases of type 2 diabetes mellitus are due to being overweight in middle age? Evidence from the midspan prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records. Diabet Med. 2007;24(1):73-80. (Pubitemid 46103074)
13. Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007;30(6):1562-1566. (Pubitemid 46871171)
14. Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health. 2005;59(2):134-139. (Pubitemid 40139326)
15. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med. 2007;356(3):213-215. (Pubitemid 46143224)
16. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581-1586. (Pubitemid 32681139)
17. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000;49(6):883-888. (Pubitemid 30349408)
18. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366(9491):1059-1062. (Pubitemid 41338752)
19. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917-932.
20. Colclough H, Hammer, M. Impact of increasing body mass index on medical resources for patients with type 2 diabetes: a retrospective analysis in the United States. ISPOR Annual European Congress in Dublin (EuroISPOR). 2007:Poster PDB48.
21. Colclough H, Aagren M, Milligan G. Impact on health care cost of increasing body mass index for people with type 2 diabetes: a cross-sectional study in United States. ISPOR Annual European Congress in Dublin (EuroISPOR), 2007:Poster PDB55.
22. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159(10):1104-1109. (Pubitemid 29230863)
23. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322(13):882- 889. (Pubitemid 20108377)
24. Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring). 2006;14(suppl 3):121S-127S.
25. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Role of risk factors for major coronary heart disease events with increasing length of follow up. Heart. 1999;81(4):374-379. (Pubitemid 29167126)
26. Pekkanen J, Tervahauta M, Nissinen A, Karvonen MJ. Does the predictive value of baseline coronary risk factors change over a 30-year follow-up? Cardiology. 1993;82(2-3):181-190. (Pubitemid 23182027)
27. Bailey CJ. Drugs on the horizon for diabesity. Curr Diab Rep. 2005;5(5):353-359. (Pubitemid 41600777)
28. Thomas J, Jones G, Scarinci I, Brantley P. A descriptive and comparative study of the prevalence of depressive and anxiety disorders in low-income adults with type 2 diabetes and other chronic illnesses. Diabetes Care. 2003;26(8):2311-2317. (Pubitemid 36993318)
29. Egede LE. Effect of comorbid chronic diseases on prevalence and odds of depression in adults with diabetes. Psychosom Med. 2005;67(1):46-51.
30. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069-1078. (Pubitemid 33716379)
31. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(suppl 11):37-41. (Pubitemid 30616693)
32. Williams B. The obese hypertensive: the weight of evidence against beta-blockers. Circulation. 2007;115(15):1973-1974. (Pubitemid 46625946)
33. Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197-1209.
34. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012. (Pubitemid 29254858)
35. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003;32(4):805-822, viii.
36. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853. (Pubitemid 28416718)
37. Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005;(2):CD004095.
38. Vermiere E, Wens J, Van Royen P, Biot Y, Heamshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003638.
39. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144(7):465-474.
40. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy - update regarding the thiazolidinediones. Diabetologia. 2008;51(1):8-11. (Pubitemid 50004100)
41. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
42. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360-372. (Pubitemid 34256388)
43. Turner RC. The UK Prospective Diabetes Study. A review. Diabetes Care. 1998;21(suppl 3):C35-C38. (Pubitemid 28545951)
44. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695-1702. (Pubitemid 30196209)
45. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab. 1998;83(9):3169-3176. (Pubitemid 28500952)
46. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev. 2002;18(suppl 2):S23-S29. (Pubitemid 34467311)
47. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226-1232. (Pubitemid 33716403)
48. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605-1611.
49. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 1998;21(9):1462-1469. (Pubitemid 28405197)
50. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1):10-17. (Pubitemid 32635256)
51. Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab. 2006;8(1):49-57.
52. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. (Pubitemid 41416583)
53. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443. (Pubitemid 44903747)
54. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096- 1105. (Pubitemid 44402668)
55. Food and Drug Administration. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk. http://www.fda.gov/bbs/topics/NEWS/ 2007/NEW01683.html. Accessed January 16, 2008.
56. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes. 1993;42(12):1700-1707. (Pubitemid 23346405)
57. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 2002;26(suppl 3):S18-S24. (Pubitemid 35034478)
58. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9(3):418-427. (Pubitemid 46502062)
59. Haak T, Tiengo A, Draeger E, Suntum M, Waldhaus W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56-64.
60. Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27(4):279-285. (Pubitemid 46440300)
61. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-416.
62. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007;9(3):209-217. (Pubitemid 46502039)
63. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-1972. (Pubitemid 44156663)
64. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696-1705. (Pubitemid 46048557)
65. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52. (Pubitemid 16162741)
66. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 1993;42(5):658-661 (Pubitemid 23127154)
67. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206. (Pubitemid 47057766)
68. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2007.
69. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-2635. (Pubitemid 39441462)
70. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100. (Pubitemid 40616618)
71. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-1091. (Pubitemid 40616617)
72. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998;68(3):525-530. (Pubitemid 28402372)
73. Gutzwiller JP, Drewe J, Goke B, et al. Glucagonlike peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999; 276(5 pt 2):R1541-R1544. (Pubitemid 29249681)
74. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29(1):139-153. (Pubitemid 46414034)
75. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487-1493. (Pubitemid 46871159)
76. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(2):195-202. (Pubitemid 34208381)
77. Chang AM, Jakobscn G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003;52(7):1786-1791. (Pubitemid 36792471)
78. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187- 1194. (Pubitemid 38569002)
79. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608-1610. (Pubitemid 46871185)
80. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27(6):1335-1342. (Pubitemid 38679980)
81. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. (Pubitemid 46711096)
82. Januvia [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; 2007.
83. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-2643. (Pubitemid 44912191)
84. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DF. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637. (Pubitemid 44912190)
85. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979-1987. (Pubitemid 47219404)
86. Novartis. Galvus, a new oral treatment for type 2 diabetes, receives positive opinion following changes to European prescribing information. http://cws.huginonline.com/N/134323/PR/200712/1176484-5-2.html. Accessed January 14, 2008.
87. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(1):132-138. (Pubitemid 46240373)
88. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175-185. (Pubitemid 46206561)
89. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30(2):217-223. (Pubitemid 46198322)
90. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24(9):955-961. (Pubitemid 47301637)
91. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7(14):1353-1373. (Pubitemid 32798815)
92. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12(4):661-668. (Pubitemid 41132509)
93. Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30(11):2794-2799. (Pubitemid 350083120)
94. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194- 1199. (Pubitemid 350273303)
95. Dixon JB, O'Brian PB, Playfair PE, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized control trial. JAMA. 2008;299(3):316-323.
96. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr. 1992;55(1 suppl):309S-313S.
97. Huizinga M. Weight-loss pharmacotherapy: a brief review. Clinical Diabetes. 2007;25(4):135-140. (Pubitemid 350277203)
98. Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases - a six-month randomized trial. Diabetes Obes Metab. 2004;6(5):375-383. (Pubitemid 39172860)
99. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033-1041. (Pubitemid 41110490)
100. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288-1294. (Pubitemid 28365685)
101. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71-77. (Pubitemid 46027230)
102. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity. Int J Obes Relat Metab Disord. 2003;27(12):1437-1446.
103. Padwal RS, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2003;(4):CD004094.
104. European Medicines Agency. Xenical scientific discussion. 2005. Available at: http://www.emea.eu.int/humandocs/PDFs/EPAR/Xenical/106698en6.pdf Accessed December 10, 2007.
105. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs. 1998;56(6):1093-1124. (Pubitemid 29010230)
106. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ, Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol. 1999;126(6):1487-1495 (Pubitemid 29142081)
107. Lean ME. How does sibutramine work? Int J Obes Relat Metab Disord. 2001;25(suppl 4):S8-S11. (Pubitemid 34098656)
108. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005;28(4):942-949. (Pubitemid 40434504)
109. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ. 2002;166(10):1307-1308. (Pubitemid 34533957)
110. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs. 2006;66(16):2109-2121.
111. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368(9548):1660-1672. (Pubitemid 46048528)
112. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761-775. (Pubitemid 43244304)
113. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600):1706-1713. (Pubitemid 350100788)
114. PR Newswire. Rimonabant regulatory update in the United States. Published June 29, 2007. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY= /www/story/06-29-2007/0004618254&EDATE=. Accessed December 10, 2007.
115. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752. (Pubitemid 47295641)
116. Jones KB. Experience with the Roux-en-Y gastric bypass and commentary on current trends. Obes Surg. 2000;10(2):183-185. (Pubitemid 30353192)
117. Adams TD, Gress RF, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753-761. (Pubitemid 47295642)
118. Diniz MF, Diniz MT, Sanchcs SR, Salgado PP, Valadao MM, Freitas CP, Vieira DJ. Glycemic control in diabetic patients after bariatric surgery. Obes Surg. 2004;14(8):1051-1055. (Pubitemid 39299729)
119. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-loywering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274. (Pubitemid 44125921)
120. Bloomgarden ZT. Prevention of obesity and diabetes. Diabetes Care. 2003;26(11):3172-3178. (Pubitemid 37339516)
121. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. (Pubitemid 32378388)
122. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. (Pubitemid 34437694)